Yasamineh S, et al. An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19. J Nanobiotechnol. 2022;20(1):1–26.
Yasamineh S, et al. Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19. Stem Cell Res Ther. 2022;13(1):1–23.
Yang KS, et al. Evolutionary and structural insights about potential SARS-CoV-2 evasion of nirmatrelvir. J Med Chem. 2022;65(13):8686–98.
Hu J, et al. The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection. Arch Virol. 2021;166(10):2649–72.
Nguyen NHL, et al. COVID-19 spike protein induced phononic modification in antibody-coupled graphene for viral detection application. ACS Nano. 2021;15(7):11743–52.
Chen RE, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27(4):717–26.
Cosar B, et al. SARS-CoV-2 mutations and their viral variants. Cytokine & growth factor reviews; 2021.
Fan Y, et al. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022;7(1):1–11.
Shiehzadegan S, et al. Analysis of the delta variant B. 1.617. 2 COVID-19. Clin Pract. 2021;11(4):778–84.
Brandal LT, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Eurosurveillance. 2021;26(50):2101147.
Burki TK. Lifting of COVID-19 restrictions in the UK and the Delta variant. Lancet Respir Med. 2021;9(8):e85.
Alexandar S, et al. A comprehensive review on Covid-19 Delta variant. Int J Pharmacol Clin Res (IJPCR). 2021;5(83–85):7.
He J, et al. Proportion of asymptomatic coronavirus disease 2019: a systematic review and meta-analysis. J Med Virol. 2021;93(2):820–30.
Nasreen S, et al. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. Nat Microbiol. 2022;7(3):379–85.
Murthy SK. Nanoparticles in modern medicine: state of the art and future challenges. Int J Nanomed. 2007;2(2):129.
Patra JK, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16(1):1–33.
Yin IX, et al. The antibacterial mechanism of silver nanoparticles and its application in dentistry. Int J Nanomed. 2020;15:2555–62.
Fam SY, et al. Stealth coating of nanoparticles in drug-delivery systems. Nanomaterials. 2020;10(4):787.
Li B, et al. The potential of biomimetic nanoparticles for tumor-targeted drug delivery. Nanomedicine. 2018;13(16):2099–118.
Sportelli MC, et al. Can nanotechnology and materials science help the fight against SARS-CoV-2? Nanomaterials. 2020;10(4):802.
Vu MN, et al. Current and future nanoparticle vaccines for COVID-19. EBioMedicine. 2021;74.
Chowdhury NK, et al. Nanoparticles as an effective drug delivery system in COVID-19. Biomed Pharmacother. 2021;143.
Kusumoputro S, et al. Potential nanoparticle applications for prevention, diagnosis, and treatment of COVID-19. View. 2020;1(4):20200105.
Norouzi M, et al. Recent advances on nanomaterials-based fluorimetric approaches for microRNAs detection. Mater Sci Eng C. 2019;104:110007.
Yasamineh S, et al., A state-of-the-art review on the recent advances of niosomes as a targeted drug delivery system. Int J Pharm. 2022;121878.
Idris A, et al. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Mol Ther. 2021;29(7):2219–26.
Reichmuth AM, et al. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7(5):319–34.
Hajj KA, Whitehead KA. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat Rev Mater. 2017;2(10):1–17.
Khurana A, et al. Role of nanotechnology behind the success of mRNA vaccines for COVID-19. Nano Today. 2021;38:101142.
Billingsley MM, et al. Ionizable lipid nanoparticle-mediated mRNA delivery for Human CAR T Cell Engineering. Nano Lett. 2020;20(3):1578–89.
Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. Mol Ther. 2017;25(7):1467–75.
Uchida S, et al. Nanomedicine-Based approaches for mRNA delivery. Mol Pharm. 2020;17(10):3654–84.
Milovanovic M, et al. Antimicrobial nanoarchitectonics. Amsterdam: Elsevier; 2017.
Yadavalli T, Shukla D. Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections. Nanomed Nanotechnol Biol Med. 2017;13(1):219–30.
Chen L, Liang J. An overview of functional nanoparticles as novel emerging antiviral therapeutic agents. Mater Sci Eng C. 2020;112:110924.
Dykman LA. Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases. Expert Rev Vaccines. 2020;19(5):465–77.
Behbudi G. Effect of silver nanoparticles disinfectant on covid-19. Adv Appl NanoBio-Technol. 2021;2(2):63–7.
Allawadhi P, et al. Silver nanoparticle based multifunctional approach for combating COVID-19. Sens Int. 2021;2:100101.
Morris D, et al. Antiviral and immunomodulatory activity of silver nanoparticles in experimental RSV infection. Viruses. 2019;11(8):732.
Salleh A, et al. The potential of silver nanoparticles for antiviral and antibacterial applications: a mechanism of action. Nanomaterials, 2020;10(8).
Allawadhi P, et al. Silver nanoparticle based multifunctional approach for combating COVID-19. Sens Int. 2021;100101.
Asgharzadeh F, et al. Therapeutic effects of silver nanoparticle containing sulfasalazine on DSS-induced colitis model. J Drug Deliv Sci Technol. 2021;61:102133.
Zachar O. Formulations for COVID-19 treatment via silver nanoparticles inhalation delivery. OSF Prepr. 2020;1–19.
Shaji J, Patole V. Protein and peptide drug delivery: oral approaches. Indian J Pharm Sci. 2008;70(3):269.
Date AA, Hanes J, Ensign LM. Nanoparticles for oral delivery: design, evaluation and state-of-the-art. J Controll Release. 2016;240:504–26.
Lima TLC, et al. Improving encapsulation of hydrophilic chloroquine diphosphate into biodegradable nanoparticles: a promising approach against herpes virus simplex-1 infection. Pharmaceutics. 2018;10(4):255.
Pichl L, et al. Magnetic bead technology in viral RNA and DNA extraction from plasma minipools. Transfusion. 2005;45(7):1106–10.
Chaimayo C, et al. Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand. Virol J. 2020;17(1):177.
Zhao Z, et al. A simple magnetic nanoparticles-based viral RNA extraction method for efficient detection of SARS-CoV-2. bioRxiv, 2020: p. 2020.02.22.961268.
Ramos-Mandujano G, et al. A robust, safe, and scalable magnetic nanoparticle workflow for RNA extraction of pathogens from clinical and wastewater samples. Glob Chall. 2021;5(4):2000068.
Hassanzadeh P. Nanotheranostics against COVID-19: from multivalent to immune-targeted materials. J Controll Release. 2020;328:112–26.
Mignani S, et al. Functionalized dendrimer platforms as a new forefront arsenal targeting SARS-CoV-2: an opportunity. Pharmaceutics. 2021;13(9):1513.
Spitz Steinberg R, et al. Breathable vapor toxicant barriers based on multilayer graphene oxide. ACS Nano. 2017;11(6):5670–9.
Palmieri V, et al. Face masks and nanotechnology: keep the blue side up. Nano Today. 2021;37:101077.
Campos EV, et al. How can nanotechnology help to combat COVID-19? Opportunities and urgent need. J Nanobiotechnol. 2020;18(1):1–23.
Chintagunta AD, Nalluru S, NS SK. Nanotechnology: an emerging approach to combat COVID-19. Emerg Mater. 2021;4(1):119–30.
Pramanik A, et al. The rapid diagnosis and effective inhibition of coronavirus using spike antibody attached gold nanoparticles. Nanoscale Adv. 2021;3(6):1588–96.
Chauhan G, et al. Nanotechnology for COVID-19: therapeutics and vaccine research. ACS Nano. 2020;14(7):7760–82.
Hamdy ME, et al. Development of gold nanoparticles biosensor for ultrasensitive diagnosis of foot and mouth disease virus. J Nanobiotechnol. 2018;16(1):48.
Dilshad E, et al. Synthesis of functional silver nanoparticles and microparticles with modifiers and evaluation of their antimicrobial, anticancer, and antioxidant activity. J Funct Biomater. 2020;11(4):76.
Nayak V, et al. Potentialities of selenium nanoparticles in biomedical science. New J Chem. 2021;45(6):2849–78.
Manzano M, Vallet-Regí M. Mesoporous silica nanoparticles for drug delivery. Adv Funct Mater. 2020;30(2):1902634.
Kotliarov Y, et al. Broad immune activation underlies shared set point signatures for vaccine responsiveness in healthy individuals and disease activity in patients with lupus. Nat Med. 2020;26(4):618–29.
Rostami H, et al. Co-utilization of a TLR5 agonist and nano-formulation of HIV-1 vaccine candidate leads to increased vaccine immunogenicity and decreased immunogenic dose: a preliminary study. Immunol Lett. 2017;187:19–26.
Kreuter J, Nanoparticles as adjuvants for vaccines. Vaccine Des. 1995;463–472.
Zeng L, et al. Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro. Nat Commun. 2022;13(1):1–16.
Jaber N, et al. A review of the antiviral activity of Chitosan, including patented applications and its potential use against COVID-19. J Appl Microbiol. 2022;132(1):41–58.
Hanafy NA, El-Kemary MA. Silymarin/curcumin loaded albumin nanoparticles coated by chitosan as muco-inhalable delivery system observing anti-inflammatory and anti COVID-19 characterizations in oleic acid triggered lung injury and in vitro COVID-19 experiment. Int J Biol Macromol. 2022;198:101–10.
Parisi OI, et al. Design and development of plastic antibodies against SARS-CoV-2 RBD based on molecularly imprinted polymers that inhibit in vitro virus infection. Nanoscale. 2021;13(40):16885–99.
de Barros AODS, et al. Polymeric nanoparticles and nanomicelles of hydroxychloroquine co-loaded with azithromycin potentiate anti-SARS-CoV-2 effect. J Nanostruct Chem. 2022;1–19.
Baldassi D, et al. Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexes. J Controll Release. 2022;345:661–74.
Rungrojcharoenkit K, et al. Development of an adjuvanted nanoparticle vaccine against influenza virus, an in vitro study. PLoS One. 2020;15(8):e0237218.
Wang J, et al. Pulmonary surfactant–biomimetic nanoparticles potentiate heterosubtypic influenza immunity. Science 2020;367(6480).
Ghaffari H, et al. Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: another emerging application of nanomedicine. J Biomed Sci. 2019;26(1):1–10.
Xiang D, et al. Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo. Int J Nanomed. 2013;8:4103.
Li Y, et al. Inhibition of H1N1 influenza virus-induced apoptosis by selenium nanoparticles functionalized with arbidol through ROS-mediated signaling pathways. J Mater Chem B. 2019;7(27):4252–62.
Kumar R, et al. Iron oxide nanoparticles based antiviral activity of H1N1 influenza a virus. J Infect Chemother. 2019;25(5):325–9.
Law S, et al. Could curcumin modified silver nanoparticles treat COVID-19? Adv Pharm Bull. 2022;12(1):5.
Xiao M-F, et al. Applications of nanomaterials in COVID-19 pandemic. Rare Metals 2021;1–13.
Mallakpour S, Azadi E, Hussain CM. The latest strategies in the fight against the COVID-19 pandemic: the role of metal and metal oxide nanoparticles. New J Chem. 2021;45(14):6167–79.
Rai M, et al. Nanotechnology-based promising strategies for the management of COVID-19: current development and constraints. Expert Rev Anti-infect Ther. 2022;20(10):1299–308.
Lin N, et al. Antiviral nanoparticles for sanitizing surfaces: a roadmap to self-sterilizing against COVID-19. Nano Today. 2021;40:101267.
Al-Radadi NS, Abu-Dief AM. Silver nanoparticles (AgNPs) as a metal nano-therapy: possible mechanisms of antiviral action against COVID-19. Inorg Nano-Metal Chem. 2022;1–19.
Mehranfar A, Izadyar M. Theoretical design of functionalized gold nanoparticles as antiviral agents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). J Phys Chem Lett. 2020;11(24):10284–9.
Palmieri V, Papi M. Can graphene take part in the fight against COVID-19? Nano Today. 2020;33:100883.
Ferrari AC, et al. Science and technology roadmap for graphene, related two-dimensional crystals, and hybrid systems. Nanoscale. 2015;7(11):4598–810.
Chauhan N, Maekawa T, Kumar DNS. Graphene based biosensors—accelerating medical diagnostics to new-dimensions. J Mater Res. 2017;32(15):2860–82.
Lee S, et al. Carbon nanotube mask filters and their hydrophobic barrier and hyperthermic antiviral effects on SARS-CoV-2. ACS Appl Nano Mater. 2021;4(8):8135–44.
Song Z, et al. Virus capture and destruction by label-free graphene oxide for detection and disinfection applications. Small. 2015;11(9–10):1171–6.
Ullah S, et al. Reusability comparison of melt-blown vs nanofiber face mask filters for use in the coronavirus pandemic. ACS Appl Nano Mater. 2020;3(7):7231–41.
Zhong H, et al. Reusable and recyclable graphene masks with outstanding superhydrophobic and photothermal performances. ACS Nano. 2020;14(5):6213–21.
Lombardo D, Kiselev MA, Caccamo MT. Smart nanoparticles for drug delivery application: development of versatile nanocarrier platforms in biotechnology and nanomedicine. J Nanomater. 2019;2019.
Eatemadi A, et al. Carbon nanotubes: properties, synthesis, purification, and medical applications. Nanoscale Res Lett. 2014;9(1):1–13.
Son KH, Hong JH, Lee JW. Carbon nanotubes as cancer therapeutic carriers and mediators. Int J Nanomed. 2016;11:5163.
Zhu S, et al. Anti-betanodavirus activity of isoprinosine and improved efficacy using carbon nanotubes based drug delivery system. Aquaculture. 2019;512:734377.
Mohajeri M, Behnam B, Sahebkar A. Biomedical applications of carbon nanomaterials: drug and gene delivery potentials. J Cell Physiol. 2019;234(1):298–319.
Zou Z, Yao M. Airflow resistance and bio-filtering performance of carbon nanotube filters and current facepiece respirators. J Aerosol Sci. 2015;79:61–71.
Vo E, et al. Application of direct-reading and elemental carbon analysis methods to measure mass-based penetration of carbon nanotubes through elastomeric half-face and filtering facepiece respirators. Aerosol Sci Technol. 2016;50(10):1044–54.
Vo E, et al. Measurement of mass-based carbon nanotube penetration through filtering facepiece respirator filtering media. Ann Occup Hyg. 2014;58(5):646–56.
Van Doremalen N, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564–7.
Wang L, Hu C, Shao L. The antimicrobial activity of nanoparticles: present situation and prospects for the future. Int J Nanomed. 2017;12:1227.
Hamouda T, et al. Preparation of cellulose-based wipes treated with antimicrobial and antiviral silver nanoparticles as novel effective high-performance coronavirus fighter. Int J Biol Macromol. 2021;181:990–1002.
Siadati SA, Afzali M, Sayyadi M. Could silver nano-particles control the 2019-nCoV virus?; An urgent glance to the past. Chem Rev Lett. 2020;3(1):9–11.
Panda S, et al. 2D MXenes for combatting COVID-19 pandemic: a perspective on latest developments and innovations. FlatChem. 2022;33:100377.
Huang Z, et al. Continuous synthesis of size-tunable silver nanoparticles by a green electrolysis method and multi-electrode design for high yield. J Mater Chem A. 2015;3(5):1925–9.
Kampf G, et al. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246–51.
Dey B, Engley F Jr. Neutralization of antimicrobial chemicals by recovery media. J Microbiol Methods. 1994;19(1):51–8.
Logothetidis S. Nanostructured materials and their applications. Cham: Springer Science & Business Media; 2012.
Maynard AD. A research strategy for addressing risk nanotechnology. Woodrow Wilson Int Center Sch. 2006;444:267–9.
Destache CJ, et al. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect Dis. 2009;9(1):1–8.
Shibata A, et al. Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment. AIDS Res Hum Retrovir. 2013;29(5):746–54.
Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93(1):250–6.
Arnaldez FI, et al. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. J Immunother Cancer 2020;8(1).
Zhou G, Chen S, Chen Z. Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies. Front Med. 2020;14(2):117–25.
Tufan A, Güler AA, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020;50(SI-1):620–32.
Ahmadpoor P, Rostaing L. Why the immune system fails to mount an adaptive immune response to a Covid-19 infection. Transpl Int. 2020;33(7):824–5.
Fung S-Y, et al. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect. 2020;9(1):558–70.
Aghbash PS, et al. SARS-CoV-2 infection: the role of PD-1/PD-L1 and CTLA-4 axis. Life Sci. 2021;270:119124.
Bahmani M, et al. Severe acute respiratory syndrome coronavirus 2 infection: role of interleukin-6 and the inflammatory cascade. World J Virol. 2022;11(3):113.
Tang Y, et al. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020;1708.
Debouttière P, et al. a. Favre-Réguillon, Y. Lin, S. Pellet-Rostaing, R. Lamartine, P. Perriat and O. Tillement. Adv Funct Mater. 2006;16(18):2330–9.
Perez JM, et al. Viral-induced self-assembly of magnetic nanoparticles allows the detection of viral particles in biological media. J Am Chem Soc. 2003;125(34):10192–3.
Xu X, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci. 2020;117(20):10970–5.
Zhang Q, et al. Recent progress in capturing and neutralizing inflammatory cytokines. CCS Chem. 2020;2(3):376–89.
Lima AC, et al. Interleukin-6 neutralization by antibodies immobilized at the surface of polymeric nanoparticles as a therapeutic strategy for arthritic diseases. ACS Appl Mater Interfaces. 2018;10(16):13839–50.
Thamphiwatana S, et al. Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management. Proc Natl Acad Sci. 2017;114(43):11488–93.
Zhang Q, et al. Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis. Nat Nanotechnol. 2018;13(12):1182–90.
Abo-zeid Y, et al. A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection. Eur J Pharm Sci. 2020;153:105465.
Vorobjeva NV, Chernyak BV. NETosis: molecular mechanisms, role in physiology and pathology. Biochemistry (Mosc). 2020;85(10):1178–90.
Zaim S, et al. COVID-19 and multiorgan response. Curr Probl Cardiol. 2020;45(8):100618.
Park HH, et al. PEGylated nanoparticle albumin-bound steroidal ginsenoside derivatives ameliorate SARS-CoV-2-mediated hyper-inflammatory responses. Biomaterials. 2021;273:120827.
Rejinold NS, et al. Injectable niclosamide nanohybrid as an anti-SARS-CoV-2 strategy. Colloids Surf B. 2021;208:112063.
Rejinold N, et al. Bovine serum albumin-coated niclosamide-zein nanoparticles as potential injectable medicine against COVID-19. Materials. 2021;14(14):3792.
Yamaoka-Tojo M. Vascular endothelial glycocalyx damage in COVID-19. Int J Mol Sci. 2020;21(24):9712.
Abo-Seidaa OM, et al. The effect of nanoparticles and electromagnetic waves on Coronavirus (COVID-19) using a rectangular waveguide cavity resonator.
Zachar O. Formulations for COVID-19 early stage treatment via silver nanoparticles inhalation delivery at home and hospital. ScienceOpen Preprints; 2020.
Tu Y-F, et al. A review of SARS-CoV-2 and the ongoing clinical trials. Int J Mol Sci. 2020;21(7):2657.
Wang H, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182(3):713–21.
Bavel JJV, et al. Using social and behavioural science to support COVID-19 pandemic response. Nat Hum Behav. 2020;4(5):460–71.
Allam M, et al. COVID-19 diagnostics, tools, and prevention. Diagnostics. 2020;10(6):409.
Scarabel L, et al. Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19. Int J Infect Dis. 2021;104:441–51.
Zaki MM, et al. Cell therapy strategies for COVID-19: current approaches and potential applications. Sci Adv. 2021;7(33):eabg5995.
Krammer F. SARS-CoV-2 vaccines in development. Nature 2020;1–16.
Dong Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target ther. 2020;5(1):1–14.
Gao Q, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 2020.
Ozdilek A, Avci FY. Glycosylation as a key parameter in the design of nucleic acid vaccines. Curr Opin Struct Biol. 2022;73:102348.
Chavda VP, et al. Nucleic acid vaccines for COVID-19: a paradigm shift in the vaccine development arena. Biologics. 2021;1(3):337–56.
McCann N, et al. Viral vector vaccines. Curr Opin Immunol. 2022;77:102210.
Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines. 2014;2(3):624–41.
Heidary M, et al. A comprehensive review of the protein subunit vaccines against COVID-19. Front Microbiol. 2022;13:927306.
Palacios R, et al. Double-Blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating Healthcare Professionals with the Adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac–PROFISCOV: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):1–3.
Bell BP. ACIP COVID-19 Vaccines Work Group 2020.
van Doremalen N, et al., ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRxiv, 2020.
Ramasamy MN, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2020.
Mercado NB, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020;586(7830):583–8.
Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet 2020.
Raja AT, Alshamsan A, Al-Jedai A. Status of the current COVID-19 vaccine candidates: implications in the Saudi Population. Saudi Pharm J. 2020.
Jackson LA, et al. An mRNA vaccine against SARS-CoV-2—preliminary report. N Engl J Med. 2020;383(20):1920–31.
Mulligan MJ, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589–93.
Rawat K, Kumari P, Saha L. COVID-19 vaccine: a recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol. 2020;173751.
López-Sagaseta J, et al. Self-assembling protein nanoparticles in the design of vaccines. Comput Struct Biotechnol J. 2016;14:58–68.
Hajj Hussein I, et al. Vaccines through centuries: major Cornerstones of Global Health. Front Public Health 2015;3.
Bayat M, Asemani Y, Najafi S. Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms. Int Immunopharmacol. 2021;97:107679.
Evans ER, et al. Metallic nanoparticles for cancer immunotherapy. Mater Today. 2018;21(6):673–85.
Smith JD, Morton LD, Ulery BD. Nanoparticles as synthetic vaccines. Curr Opin Biotechnol. 2015;34:217–24.
Chintagunta AD, Nalluru S, NS SK, Nanotechnology: an emerging approach to combat COVID-19. Emerg Mater. 2021;1–12.
Chandler M, et al. Innate immune responses triggered by nucleic acids inspire the design of immunomodulatory nucleic acid nanoparticles (NANPs). Curr Opin Biotechnol. 2020;63:8–15.
Pardi N, et al. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–79.
Schlich M, et al. Cytosolic delivery of nucleic acids: the case of ionizable lipid nanoparticles. Bioeng Transl Med. 2021;6(2):e10213.
Kreimer AR, et al. Evidence for single-dose protection by the bivalent HPV vaccine—review of the Costa Rica HPV vaccine trial and future research studies. Vaccine. 2018;36(32):4774–82.
Deng Y, et al. Rational development of a polysaccharide–protein-conjugated nanoparticle vaccine against SARS‐CoV‐2 variants and Streptococcus pneumoniae. Adv Mater. 2022;2200443.
Song JY, et al. Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: a randomised, placebo-controlled, observer-blinded phase 1/2 trial. EClinicalMedicine. 2022;51:101569.
Johnston SC, et al. A SARS-CoV-2 spike ferritin nanoparticle vaccine is protective and promotes a strong immunological response in the cynomolgus macaque coronavirus disease 2019 (COVID-19) model. Vaccines. 2022;10(5):717.
Udugama B, et al. Diagnosing COVID-19: the disease and tools for detection. ACS Nano. 2020;14(4):3822–35.
Roewe J, et al. Bacterial polyphosphates interfere with the innate host defense to infection. Nat Commun. 2020;11(1):4035.
Palestino G, et al. Can nanotechnology help in the fight against COVID-19? Expert Rev Anti Infect Ther. 2020;18(9):849–64.
Puri N, et al. Synthesis and characterization of reduced graphene oxide supported gold nanoparticles-poly(pyrrole-co-pyrrolepropylic acid) nanocomposite-based electrochemical biosensor. Appl Biochem Biotechnol. 2014;174(3):911–25.
Weiss C, et al. Toward nanotechnology-enabled approaches against the COVID-19 pandemic. ACS Nano. 2020;14(6):6383–406.
Seo G, et al. Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor. ACS Nano. 2020;14(4):5135–42.
Vaquer A, et al. Nanoparticle transfer biosensors for the non-invasive detection of SARS-CoV-2 antigens trapped in Surgical Face Masks. Sens Actuators B Chem 2021;130347.
Corman VM, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. 2020;25(3):2000045.
Chu DK, et al. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin Chem. 2020;66(4):549–55.
Wang Z, et al. A point-of-care selenium nanoparticle-based test for the combined detection of anti-SARS-CoV-2 IgM and IgG in human serum and blood. Lab Chip. 2020;20(22):4255–61.
Zhu X, et al. Reverse transcription loop-mediated isothermal amplification combined with nanoparticles-based biosensor for diagnosis of COVID-19. MedRxiv, 2020.
Li S, et al. Highly sensitive and specific diagnosis of COVID-19 by reverse transcription multiple cross-displacement amplification-labelled nanoparticles biosensor. Eur Respir J. 2020;56(6).
Zhu X, et al. Multiplex reverse transcription loop-mediated isothermal amplification combined with nanoparticle-based lateral flow biosensor for the diagnosis of COVID-19. Biosens Bioelectron. 2020;166:112437.
Hoffmann M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80.
Ou X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1–12.
Ting D, et al. Multisite inhibitors for enteric coronavirus: antiviral cationic carbon dots based on curcumin. ACS Appl Nano Mater. 2018;1(10):5451–9.
Ngan DK, et al. Repurposing drugs as COVID-19 therapies: a toxicity evaluation. Drug Discov Today 2022.
Gautret P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.
Mehra MR, et al. RETRACTED: hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Elsevier; 2020.
Elavarasi A, et al. Chloroquine and hydroxychloroquine for the treatment of COVID-19: a systematic review and meta-analysis. J Gen Intern Med. 2020;35(11):3308–14.
Patel TK, et al. Efficacy and safety of lopinavir-ritonavir in COVID-19: a systematic review of randomized controlled trials. J Infect Public Health. 2021;14(6):740–8.
Menéndez JC. Approaches to the potential therapy of COVID-19: a general overview from the medicinal chemistry perspective. Molecules. 2022;27(3):658.
Cao B, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020.
Costanzo M, De Giglio MA, Roviello GN. SARS-CoV-2: recent reports on antiviral therapies based on lopinavir/ritonavir, darunavir/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Curr Med Chem. 2020;27(27):4536–41.
Cai Q, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). 2020;6(10):1192–8.
Ivashchenko AA, et al. Effect of aprotinin and Avifavir® combination therapy for moderate COVID-19 patients. Viruses. 2021;13(7):1253.
McClements J, et al. Molecularly imprinted polymer nanoparticles enable rapid, reliable, and robust point-of-care thermal detection of SARS-CoV-2. ACS Sens. 2022;7(4):1122–31.
Hubbard LR, et al. Detection of SARS-COV-2 by functionally imprinted micelles MRS communications. 2022;1–8.
Khurana A, et al. Superoxide dismutase mimetic nanoceria restrains cerulein induced acute pancreatitis. Nanomedicine. 2019;14(14):1805–25.
Kumar GS, et al. Selenium nanoparticles involve HSP-70 and SIRT1 in preventing the progression of type 1 diabetic nephropathy. Chemico-Biol Interact. 2014;223:125–33.
Kirwale S, et al. Selenium nanoparticles induce autophagy mediated cell death in human keratinocytes. Nanomedicine. 2019;14(15):1991–2010.
De M, Ghosh PS, Rotello VM. Applications of nanoparticles in biology. Adv Mater. 2008;20(22):4225–41.
Islam NU, et al. A multi-target therapeutic potential of Prunus domestica gum stabilized nanoparticles exhibited prospective anticancer, antibacterial, urease-inhibition, anti-inflammatory and analgesic properties. BMC Complement Altern Med. 2017;17(1):276.
Yusuf A, Casey A. Surface modification of silver nanoparticle (AgNP) by liposomal encapsulation mitigates AgNP-induced inflammation. Toxicol In Vitro. 2019;61:104641.
Khurana A, et al. Superoxide dismutase mimetic nanoceria restrains cerulein induced acute pancreatitis. Nanomedicine (Lond). 2019;14(14):1805–25.
Mansour HH, Eid M, El-Arnaouty MB. Effect of silver nanoparticles synthesized by gamma radiation on the cytotoxicity of doxorubicin in human cancer cell lines and experimental animals. Hum Exp Toxicol. 2017;37(1):38–50.
Allawadhi P, et al. Nanoceria as a possible agent for the management of COVID-19. Nano Today. 2020;35:100982.
Allawadhi P, et al. Potential of electric stimulation for the management of COVID-19. Med Hypotheses. 2020;144:110259.
Khurana A, et al. Yttrium oxide nanoparticles reduce the severity of acute pancreatitis caused by cerulein hyperstimulation. Nanomed Nanotechnol Biol Med. 2019;18:54–65.
Sun J, et al. Characterization and evaluation of a novel silver nanoparticles-loaded polymethyl methacrylate denture base: in vitro and < i > in vivo animal study. Dent Mater J. 2021;40(5):1100–8.
Lu H, et al. Modulatory role of silver nanoparticles and mesenchymal stem cell-derived exosome-modified barrier membrane on macrophages and osteogenesis. Front Chem. 2021. https://doi.org/10.3389/fchem.2021.699802.
Gonzalez-Carter DA, et al. Silver nanoparticles reduce brain inflammation and related neurotoxicity through induction of H2S-synthesizing enzymes. Sci Rep. 2017;7(1):42871.
Hebeish A, et al. Antimicrobial wound dressing and anti-inflammatory efficacy of silver nanoparticles. Int J Biol Macromol. 2014;65:509–15.